Literature DB >> 20165556

Focus on flaviviruses: current and future drug targets.

Brian J Geiss1, Hillary Stahla, Amanda M Hannah, Amanda M Gari, Susan M Keenan.   

Abstract

BACKGROUND: Infection by mosquito-borne flaviviruses (family Flaviviridae) is increasing in prevalence worldwide. The vast global, social and economic impact due to the morbidity and mortality associated with the diseases caused by these viruses necessitates therapeutic intervention. There is currently no effective clinical treatment for any flaviviral infection. Therefore, there is a great need for the identification of novel inhibitors to target the virus life cycle. DISCUSSION: In this article, we discuss structural and nonstructural viral proteins that are the focus of current target validation and drug discovery efforts. Both inhibition of essential enzymatic activities and disruption of necessary protein–protein interactions are considered. In addition, we address promising new targets for future research.
CONCLUSION: As our molecular and biochemical understanding of the flavivirus life cycle increases, the number of targets for antiviral therapeutic discovery grows and the possibility for novel drug discovery continues to strengthen.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20165556      PMCID: PMC2822355          DOI: 10.4155/fmc.09.27

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  130 in total

1.  Structure of West Nile virus.

Authors:  Suchetana Mukhopadhyay; Bong-Suk Kim; Paul R Chipman; Michael G Rossmann; Richard J Kuhn
Journal:  Science       Date:  2003-10-10       Impact factor: 47.728

2.  La protein binds to NS5 and NS3 and to the 5' and 3' ends of Dengue 4 virus RNA.

Authors:  Beatriz María García-Montalvo; Fernando Medina; Rosa M del Angel
Journal:  Virus Res       Date:  2004-06-15       Impact factor: 3.303

3.  Crystal structure of human toll-like receptor 3 (TLR3) ectodomain.

Authors:  Jungwoo Choe; Matthew S Kelker; Ian A Wilson
Journal:  Science       Date:  2005-06-16       Impact factor: 47.728

4.  Crystal structure and activity of Kunjin virus NS3 helicase; protease and helicase domain assembly in the full length NS3 protein.

Authors:  Eloise Mastrangelo; Mario Milani; Michela Bollati; Barbara Selisko; Frederic Peyrane; Vittorio Pandini; Graziella Sorrentino; Bruno Canard; Peter V Konarev; Dmitri I Svergun; Xavier de Lamballerie; Bruno Coutard; Alexander A Khromykh; Martino Bolognesi
Journal:  J Mol Biol       Date:  2007-06-27       Impact factor: 5.469

5.  Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses.

Authors:  J F Bazan; R J Fletterick
Journal:  Virology       Date:  1989-08       Impact factor: 3.616

6.  Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection.

Authors:  Srikanth Venkatraman; Stéphane L Bogen; Ashok Arasappan; Frank Bennett; Kevin Chen; Edwin Jao; Yi-Tsung Liu; Raymond Lovey; Siska Hendrata; Yuhua Huang; Weidong Pan; Tejal Parekh; Patrick Pinto; Veljko Popov; Russel Pike; Sumei Ruan; Bama Santhanam; Bancha Vibulbhan; Wanli Wu; Weiying Yang; Jianshe Kong; Xiang Liang; Jesse Wong; Rong Liu; Nancy Butkiewicz; Robert Chase; Andrea Hart; Sony Agrawal; Paul Ingravallo; John Pichardo; Rong Kong; Bahige Baroudy; Bruce Malcolm; Zhuyan Guo; Andrew Prongay; Vincent Madison; Lisa Broske; Xiaoming Cui; Kuo-Chi Cheng; Yunsheng Hsieh; Jean-Marc Brisson; Danial Prelusky; Walter Korfmacher; Ronald White; Susan Bogdanowich-Knipp; Anastasia Pavlovsky; Prudence Bradley; Anil K Saksena; Ashit Ganguly; John Piwinski; Viyyoor Girijavallabhan; F George Njoroge
Journal:  J Med Chem       Date:  2006-10-05       Impact factor: 7.446

7.  Expression, purification, and characterization of the RNA 5'-triphosphatase activity of dengue virus type 2 nonstructural protein 3.

Authors:  Greg Bartelma; R Padmanabhan
Journal:  Virology       Date:  2002-07-20       Impact factor: 3.616

8.  Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN.

Authors:  Elena Pokidysheva; Ying Zhang; Anthony J Battisti; Carol M Bator-Kelly; Paul R Chipman; Chuan Xiao; G Glenn Gregorio; Wayne A Hendrickson; Richard J Kuhn; Michael G Rossmann
Journal:  Cell       Date:  2006-02-10       Impact factor: 41.582

9.  An in vitro fluorescence screen to identify antivirals that disrupt hepatitis B virus capsid assembly.

Authors:  Stephen J Stray; Jennifer M Johnson; Benjamin G Kopek; Adam Zlotnick
Journal:  Nat Biotechnol       Date:  2006-02-12       Impact factor: 54.908

10.  HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus.

Authors:  Paul A Johnston; Jennifer Phillips; Tong Ying Shun; Sunita Shinde; John S Lazo; Donna M Huryn; Michael C Myers; Boris I Ratnikov; Jeffrey W Smith; Ying Su; Russell Dahl; Nicholas D P Cosford; Sergey A Shiryaev; Alex Y Strongin
Journal:  Assay Drug Dev Technol       Date:  2007-12       Impact factor: 1.738

View more
  25 in total

1.  Identification of a novel antiviral inhibitor of the flavivirus guanylyltransferase enzyme.

Authors:  Hillary J Stahla-Beek; Daniel G April; Bejan J Saeedi; Amanda M Hannah; Susan M Keenan; Brian J Geiss
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

2.  Policresulen, a novel NS2B/NS3 protease inhibitor, effectively inhibits the replication of DENV2 virus in BHK-21 cells.

Authors:  Deng-wei Wu; Fei Mao; Yan Ye; Jian Li; Chuan-lian Xu; Xiao-min Luo; Jing Chen; Xu Shen
Journal:  Acta Pharmacol Sin       Date:  2015-08-17       Impact factor: 6.150

3.  A high-throughput screening assay for the identification of flavivirus NS5 capping enzyme GTP-binding inhibitors: implications for antiviral drug development.

Authors:  Brian J Geiss; Hillary J Stahla-Beek; Amanda M Hannah; Hamid H Gari; Brittney R Henderson; Bejan J Saeedi; Susan M Keenan
Journal:  J Biomol Screen       Date:  2011-07-25

4.  Dengue virus nonstructural protein 5 adopts multiple conformations in solution.

Authors:  Cécile Bussetta; Kyung H Choi
Journal:  Biochemistry       Date:  2012-07-16       Impact factor: 3.162

5.  Antiviral cationic peptides as a strategy for innovation in global health therapeutics for dengue virus: high yield production of the biologically active recombinant plectasin peptide.

Authors:  Hussin A Rothan; Zulqarnain Mohamed; Abdulrazzaq M Suhaeb; Noorsaadah Abd Rahman; Rohana Yusof
Journal:  OMICS       Date:  2013-09-17

6.  The C-terminal 50 amino acid residues of dengue NS3 protein are important for NS3-NS5 interaction and viral replication.

Authors:  Moon Y F Tay; Wuan Geok Saw; Yongqian Zhao; Kitti W K Chan; Daljit Singh; Yuwen Chong; Jade K Forwood; Eng Eong Ooi; Gerhard Grüber; Julien Lescar; Dahai Luo; Subhash G Vasudevan
Journal:  J Biol Chem       Date:  2014-12-08       Impact factor: 5.157

7.  Structure-function analysis of hepatitis C virus envelope glycoproteins E1 and E2.

Authors:  Aparajita Nayak; Nagarajan Pattabiraman; Numrah Fadra; Radoslav Goldman; Sergei L Kosakovsky Pond; Raja Mazumder
Journal:  J Biomol Struct Dyn       Date:  2014-10-15

8.  A comparative study of short linear motif compositions of the influenza A virus ribonucleoproteins.

Authors:  Chu-Wen Yang
Journal:  PLoS One       Date:  2012-06-08       Impact factor: 3.240

9.  Protegrin-1 inhibits dengue NS2B-NS3 serine protease and viral replication in MK2 cells.

Authors:  Hussin A Rothan; Ammar Y Abdulrahman; Pottayil G Sasikumer; Shatrah Othman; Noorsaadah Abd Rahman; Rohana Yusof
Journal:  J Biomed Biotechnol       Date:  2012-10-02

10.  Inhibition of dengue NS2B-NS3 protease and viral replication in Vero cells by recombinant retrocyclin-1.

Authors:  Hussin A Rothan; Heh Choon Han; Thamil Selvee Ramasamy; Shatrah Othman; Noorsaadah Abd Rahman; Rohana Yusof
Journal:  BMC Infect Dis       Date:  2012-11-21       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.